Skip to content

Cytokinetics CYTK Reldesemtiv — Number Of Clinical Trials Conducted

Discontinued — last reported Q4 '17

Similar metrics at other companies

Exelixis logo
EXELResulting From Discovery Efforts — Number of products that entered in the commercial marketplace
40.0%
Exelixis logo
EXELResulting From Discovery Efforts — Numberof Productsin Commercial Market
0.5-50.0%
Baxter International logo
BAXRECOTHROM and PREVELEAK — Number of products acquired
2
Labcorp Holdings logo
LHDrug Development — Revenue
$737.7M+2.6%
Medpace Holdings, Inc. logo
MEDPMetabolic — Total Revenue
$201.24M+18.0%
IQVIA logo
IQVResearch & Development Solutions — Revenue
$2.4B+6.2%

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept cytk:NumberOfClinicalTrialsConducted.

The official record: Cytokinetics’s 10-K, filed March 7, 2019, on SEC EDGAR. View the filing →

Questions, answered.

What does reldesemtiv — number of clinical trials conducted mean?
The total number of clinical studies currently or previously conducted to test the efficacy and safety of the reldesemtiv drug candidate.
How do you interpret reldesemtiv — number of clinical trials conducted?
An increase suggests an expanding clinical development program and potential for broader therapeutic applications, while a decrease may indicate program maturation, completion of studies, or strategic reprioritization.
How does reldesemtiv — number of clinical trials conducted compare across companies?
Biotechnology peers typically report clinical trial counts by asset to demonstrate pipeline progress; higher counts generally correlate with advanced-stage assets nearing commercialization.